Vertex Pharmaceuticals Financial Model
Pharmaceuticals Company Financials Example (Free Excel Download)
Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercialises transformative medicines for people with serious diseases.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and pipeline scenario planning tool for Vertex Pharmaceuticals, enabling an analyst to forecast the cash flow durability of the cystic fibrosis (CF) franchise while probability-weighting the commercial ramp of recent and upcoming launches such as Casgevy, Journavx, and povetacicept.
Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercialises transformative medicines for people with serious diseases. The company established its foundation by developing the first and only medicines that treat the underlying cause of cystic fibrosis, and it is now diversifying its commercial portfolio into gene therapy, non-opioid pain management, and autoimmune diseases.
Business segments: Vertex operates as a single business segment focused on human therapeutics, but revenue is driven by distinct product franchises:
- Cystic Fibrosis Franchise (Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco, and the newly approved Alyftrek): ~99% of 2024 revenue.
- Gene Therapy (Casgevy): <1% of 2024 revenue, but a key future growth driver.
- Acute Pain (Journavx): Newly approved in late 2024/early 2025.
Key geographies: The United States accounts for approximately 60% of total product revenue, with international markets (primarily Europe and Australia) contributing the remaining 40%.
Business model type: Asset-light manufacturing with heavy intellectual property and R&D investment. Vertex relies on third-party contract manufacturing organisations (CMOs) for active pharmaceutical ingredients and drug product manufacturing.
Competitive position: Vertex holds a near-monopoly in the cystic fibrosis market, treating the vast majority of eligible patients globally. In new markets like sickle cell disease (SCD) and acute pain, it faces competition from established standard-of-care treatments and other novel therapies (e.g., Bluebird Bio for SCD).
Recent major events: In Q2 2024, Vertex acquired Alpine Immune Sciences for $4.9 billion in cash, gaining povetacicept for IgA nephropathy (IgAN). This resulted in a massive $4.4 billion acquired in-process R&D (IPR&D) charge, pushing the company into a GAAP net loss for the 2024 fiscal year despite generating $11.02 billion in revenue. In late 2024 and early 2025, Vertex secured FDA approvals for Alyftrek (a new once-daily CF triple combination) and Journavx (suzetrigine for acute pain).
The downloadable Vertex Pharmaceuticals financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsVertex Pharmaceuticals financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $7.57B | $8.93B | $9.87B | $11.02B | $12.00B |
| Gross profit | $6.67B | $7.85B | $8.61B | $9.49B | $10.35B |
| Operating income | $2.78B | $4.31B | $3.83B | -$232.9M | $4.17B |
| Net income | $2.34B | $3.32B | $3.62B | -$535.6M | $3.95B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Vertex Pharmaceuticals
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Trikafta / Kaftrio
- Segment name: TRIKAFTA/KAFTRIO
- Revenue driver formula: Eligible Patient Population x Market Penetration % x Annual Net Price
- Historical growth rate: 12-15% CAGR over the last 3 years (reaching $10.24 billion in 2024).
- Key growth levers and headwinds: Growth is driven by label expansions to younger age groups (e.g., ages 2 to 5) and new reimbursement agreements in ex-US markets. Headwinds include market saturation, as the vast majority of eligible patients are already on therapy, and potential cannibalisation from Vertex's own next-generation CF drugs (Alyftrek).
- Pricing dynamics: High-priced specialty orphan drug. US list price is over $300,000 annually, though net price is lower after mandatory government discounts and commercial rebates. Ex-US pricing is negotiated at the national level and is typically lower than US pricing.
- Revenue recognition notes: Recognised upon delivery to specialty pharmacies and distributors, net of variable consideration (rebates, chargebacks, and returns).
- Seasonality: Q1 is typically the weakest quarter due to US insurance plan resets and co-pay dynamics, while Q4 is historically the strongest.
Other CF Products (Symdeko, Orkambi, Kalydeco)
- Segment name: Other CF Products
- Revenue driver formula: Remaining Patient Base x Annual Net Price
- Historical growth rate: Negative (declining as patients migrate to Trikafta/Kaftrio).
- Key growth levers and headwinds: These legacy products are in structural decline. They are only used by a small subset of patients who cannot tolerate Trikafta or have specific rare mutations.
- Pricing dynamics: Similar to Trikafta but heavily discounted in some regions as they are older therapies.
- Revenue recognition notes: Standard product delivery.
- Seasonality: Similar Q1 weakness due to US insurance resets.
Casgevy (Gene Therapy)
- Segment name: CASGEVY
- Revenue driver formula: Number of Authorised Treatment Centres (ATCs) x Patients Infused per ATC x Net Price per Infusion
- Historical growth rate: N/A (Launched in 2024, generated ~$10 million in 2024).
- Key growth levers and headwinds: Growth depends entirely on the activation of ATCs and the lengthy patient journey (cell collection, myeloablative conditioning, and infusion). Headwinds include the severe physical toll of the conditioning regimen on patients and complex reimbursement negotiations.
- Pricing dynamics: One-time curative therapy priced at $2.2 million in the US.
- Revenue recognition notes: Revenue is recognised when the final edited cells are infused into the patient, meaning there is a significant lag (often 6-9 months) between patient identification and revenue recognition.
- Seasonality: None established yet, driven by manufacturing and treatment centre scheduling.
Journavx (Suzetrigine)
- Segment name: JOURNAVX
- Revenue driver formula: Number of Prescriptions x Net Price per Prescription
- Historical growth rate: N/A (Approved late 2024 / early 2025).
- Key growth levers and headwinds: Levers include the massive unmet need for non-opioid pain relief and legislative pushes to reduce opioid prescribing. Headwinds include hospital formulary adoption hurdles and generic competition from cheap NSAIDs and generic opioids.
- Pricing dynamics: Priced at a premium to generic pain medications but must demonstrate health economic value to secure hospital formulary placement.
- Revenue recognition notes: Standard pharmaceutical product delivery to wholesalers.
- Seasonality: Acute pain prescriptions may see slight upticks in summer months due to higher rates of elective orthopaedic surgeries and trauma.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: COGS primarily consists of royalty payments (notably to the Cystic Fibrosis Foundation), costs of contract manufacturing, quality assurance, and freight.
- Gross margin range: 87% to 89% historically.
- Key input costs and commodity exposures: Active pharmaceutical ingredients sourced from third-party CMOs. Minimal traditional commodity exposure.
- How COGS scales with revenue: Highly linear. Royalties are a fixed percentage of sales, and manufacturing costs for small molecules are negligible relative to the high selling price. Casgevy will have a higher COGS profile due to the bespoke, patient-specific cell manufacturing process.
Operating Expenses
- R&D: Typically 25% to 30% of revenue on a non-GAAP basis. Vertex does not capitalise R&D until regulatory approval is achieved. R&D covers clinical trials, preclinical research, and milestone payments to collaboration partners (e.g., CRISPR Therapeutics).
- SG&A: Typically 11% to 13% of revenue. Driven by the commercial sales force, marketing for new launches (Casgevy, Journavx), and corporate overhead.
- Depreciation & Amortisation: Very low (1-2% of revenue) due to the outsourced manufacturing model.
- Stock-Based Compensation: Significant, typically running at 4% to 5% of revenue, which is standard for large-cap biotech.
- Restructuring / one-time charges: Acquired IPR&D is a massive and frequent line item. In 2024, Vertex recorded a $4.4 billion IPR&D charge for the Alpine Immune Sciences acquisition.
Margin Profile
- Gross margin: 87-89%.
- EBITDA margin: 45-50% (adjusted for IPR&D).
- Operating margin: 43-48% (non-GAAP). GAAP operating margins fluctuate wildly depending on M&A activity.
- Net margin: 35-40% (non-GAAP).
- Margin trend: Stable to slightly compressing in the near term as the company invests heavily in the commercial launches of Casgevy and Journavx, which have higher initial SG&A burdens than the mature CF franchise.
Balance Sheet Structure
- Total assets: Approximately $22 billion to $24 billion.
- Key asset categories: Cash and marketable securities, inventory, accounts receivable, and intangible assets/goodwill.
- Goodwill & intangibles as % of total assets: Approximately 15-20%, driven by historical acquisitions (Semma, Exonics, Alpine).
- Working capital profile:
- Days Sales Outstanding (DSO): 45-55 days.
- Days Inventory Outstanding (DIO): 150-180 days (pharma companies hold significant safety stock).
- Days Payable Outstanding (DPO): 40-50 days.
- Net working capital as % of revenue: Typically positive 15-20%.
- Is working capital positive or negative? Positive. The company funds its operations easily through massive operating cash flow.
- PP&E: Minimal relative to market cap (approx $1.5 billion), consisting mostly of lab space and corporate headquarters in Boston.
- Right-of-use assets / operating leases: Material but manageable, representing long-term leases for research facilities.
Capital Expenditure & Investment
- Capex as % of revenue: 2% to 3%.
- Maintenance capex vs. growth capex: Mostly growth capex related to expanding R&D laboratory footprints and building out internal cell therapy manufacturing capabilities.
- Major capex programmes underway or planned: Buildout of cell and genetic therapy manufacturing facilities in the Boston area.
- Capitalised software / development costs if material: Immaterial.
- M&A pattern: Transformational bolt-ons. Vertex acquires clinical-stage companies to build new franchises (e.g., Alpine for $4.9B in 2024 for IgAN, Semma for Type 1 Diabetes).
- Typical acquisition multiple paid: Valuations are based on pipeline potential rather than trailing revenue, often resulting in multi-billion dollar upfront payments for zero-revenue companies.
Debt & Capital Structure
- Total debt: Effectively zero traditional funded debt. The balance sheet shows lease liabilities but no major bonds or term loans.
- Debt/EBITDA ratio: 0.0x.
- Credit rating: Unrated / Investment Grade equivalent due to massive net cash position.
- Key debt instruments: Revolving credit facility (typically undrawn).
- Maturity profile: N/A.
- Interest rate profile: Vertex earns significant interest income on its $11.2 billion cash pile, acting as a net interest earner.
- Covenants: None material.
- Share repurchase programme: Highly active. Vertex regularly repurchases shares to offset dilution from stock-based compensation and return excess capital.
- Dividend policy: No dividend. Capital is returned via buybacks and reinvested in R&D/M&A.
Cash Flow Characteristics
- Operating cash flow conversion: OCF / Non-GAAP Net Income is typically 1.0x to 1.2x.
- Free cash flow margin: 35% to 45% (excluding major cash acquisitions).
- Major non-cash items that bridge net income to OCF: Stock-based compensation, deferred income taxes, and acquired IPR&D charges (which are often expensed but paid in cash, requiring careful cash flow statement mapping).
- Working capital cash flow impact: Inventory builds for new product launches (Casgevy, Journavx) act as a moderate use of cash.
- Capex intensity: Very low.
- Cash tax rate vs. GAAP effective tax rate: The cash tax rate is often lower than the statutory rate due to the utilisation of R&D tax credits and orphan drug credits. The non-GAAP effective tax rate is typically 19-21%.
Sheet Structure
- Assumptions: Hardcoded inputs for macroeconomic drivers, CF patient populations, pricing, pipeline probability of success, and margin targets.
- CF_Franchise_Build: Patient-driven revenue build for Trikafta/Kaftrio, Alyftrek, and legacy CF products. Includes eligible populations, penetration rates, and net pricing by region (US vs Ex-US).
- Pipeline_Build: Revenue builds for Casgevy (driven by ATC activation and patient throughput), Journavx (prescription volume), and povetacicept (probability-weighted peak sales).
- Income_Statement: Consolidated P&L mirroring the 10-K. Must include specific lines for "Product revenues, net", "Cost of sales", "Research and development expenses", "Selling, general and administrative expenses", and "Acquired in-process research and development expenses".
- Balance_Sheet: Standard assets and liabilities. Key lines include "Cash, cash equivalents and marketable securities", "Inventory", "Intangible assets", and "Operating lease right-of-use assets".
- Cash_Flow: Indirect method starting from Net Income. Must explicitly break out "Acquired in-process research and development" as an add-back if it was a non-cash asset acquisition, or handle it in investing cash flows if it was a business combination.
- Debt_and_Interest: Schedule tracking cash balances, interest income earned on cash, and lease liability amortisation.
- Working_Capital: Schedules for Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO.
- Tax_Schedule: Calculation of GAAP and Non-GAAP tax provisions, incorporating R&D tax credits.
- Valuation: DCF using unlevered free cash flow, WACC calculation, and terminal value based on a perpetuity growth rate.
- Non_GAAP_Reconciliation: Crucial sheet that bridges GAAP Net Income to Non-GAAP Net Income by adding back SBC, amortisation of intangibles, and acquired IPR&D.
Key Financial Relationships
- Trikafta US Revenue = US Eligible CF Patients x US Market Penetration % x US Annual Net Price
- Trikafta Ex-US Revenue = Ex-US Eligible CF Patients x Ex-US Market Penetration % x Ex-US Annual Net Price
- Casgevy Revenue = Number of Active ATCs x Average Infusions per ATC x Net Price per Infusion
- Journavx Revenue = Target Acute Pain Prescriptions x Market Share % x Net Price per Rx
- Total Product Revenues, Net = Trikafta/Kaftrio Revenue + Alyftrek Revenue + Other CF Products Revenue + Casgevy Revenue + Journavx Revenue
- Cost of Sales = Total Product Revenues x Blended Gross Margin % (historically 11-13% of revenue)
- Non-GAAP R&D Expense = Total Product Revenues x Target R&D Margin (historically 25-30%)
- Non-GAAP SG&A Expense = Total Product Revenues x Target SG&A Margin (historically 11-13%)
- Interest Income = Average Cash and Marketable Securities Balance x Yield on Cash
- Non-GAAP Net Income = Total Product Revenues - Cost of Sales - Non-GAAP R&D - Non-GAAP SG&A + Interest Income - Non-GAAP Tax Provision
- Free Cash Flow = Operating Cash Flow - Capital Expenditures
- Diluted Shares Outstanding = Base Shares - (Share Repurchase Spend / Average Share Price) + Options Dilution
Cross-Sheet Dependencies
- The Assumptions sheet feeds the CF_Franchise_Build and Pipeline_Build sheets.
- The CF_Franchise_Build and Pipeline_Build sheets aggregate into the "Product revenues, net" line on the Income_Statement.
- The Income_Statement generates Net Income, which is the starting point for the Cash_Flow statement.
- The Cash_Flow statement calculates the net change in cash, which feeds the "Cash, cash equivalents and marketable securities" line on the Balance_Sheet.
- The Balance_Sheet cash balance feeds the Debt_and_Interest schedule to calculate Interest Income.
- Interest Income flows back to the Income_Statement, creating a minor circularity that must be managed with a toggle switch or iterative calculation.
- The Non_GAAP_Reconciliation sheet pulls GAAP figures from the Income_Statement and SBC/Amortisation from the Cash_Flow statement to calculate Non-GAAP EPS.
Sign Convention
- Revenues and Assets are positive.
- Expenses (COGS, R&D, SG&A) are entered as positive numbers in their respective schedules but subtracted in the Income Statement totals.
- Cash outflows (Capex, Share Repurchases) are negative on the Cash Flow statement.
- Cash inflows (Net Income, Depreciation add-back) are positive on the Cash Flow statement.
- Contra-assets (Accumulated Depreciation) are negative on the Balance Sheet.
Things Most Likely to Go Wrong
- "Acquired IPR&D charges frequently distort GAAP earnings. The model must clearly separate GAAP and Non-GAAP metrics, as Vertex is valued entirely on Non-GAAP earnings."
- "In years with massive IPR&D charges (like 2024), Vertex reports a GAAP net loss. This changes the calculation of diluted shares outstanding (anti-dilution rules apply to GAAP, but not to Non-GAAP). The model must use the correct share count for Non-GAAP EPS."
- "Casgevy revenue recognition is delayed by months compared to patient identification. Modelling Casgevy based purely on 'eligible patients' will drastically overstate near-term revenue; it must be modelled on completed infusions."
- "Vertex earns significant interest income on its $11+ billion cash pile. Ignoring this will understate EPS by a material amount."
- "The CF franchise is approaching peak penetration. Applying historical double-digit growth rates to Trikafta indefinitely will result in impossible market shares. Growth must decelerate."
- "Stock-based compensation is a massive non-cash expense. Excluding it from valuation without adjusting the share count will artificially inflate the company's value."
- "Alyftrek will cannibalise Trikafta. The model must ensure that total CF patients do not exceed the epidemiological reality; a patient gaining Alyftrek must be subtracted from Trikafta."
- "Tax rates fluctuate based on R&D tax credits. Using the US statutory 21% rate is incorrect; the model must use the company's guided non-GAAP effective tax rate."
Validation Checks
- "Gross margin must remain between 87% and 89%; flag if it drops below 85% or exceeds 90%."
- "Total CF patients treated in the model cannot exceed the estimated total addressable market of ~90,000 patients globally."
- "Non-GAAP Operating Margin should be in the 43% to 48% range; flag if outside this band."
- "Cash balance must never go negative; Vertex generates too much cash for this to be realistic without a hardcoded mega-acquisition."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Capex as a % of revenue should not exceed 5%; flag if it does, as this violates the outsourced manufacturing model."
- "Non-GAAP effective tax rate should be between 19% and 21%."
- "Interest income must equal approximately 4-5% of the average cash balance."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| 2025 Total Revenue Guidance | 11,875 | USD Millions | Midpoint of management's 2025 guidance ($11.75B to $12.0B). |
| Trikafta/Kaftrio 2024 Base Revenue | 10,240 | USD Millions | Actual reported 2024 revenue. |
| CF Franchise Long-Term Growth Rate | 2.0 | % | Reflects market saturation and price stability, transitioning to a mature cash cow. |
| Casgevy 2025 Revenue Estimate | 116 | USD Millions | Management guidance for 2025 Casgevy ramp. |
| Blended Gross Margin | 88.0 | % | Historical average, driven by royalty obligations. |
| Non-GAAP R&D as % of Revenue | 26.0 | % | Required to support broad pipeline (pain, IgAN, Type 1 Diabetes). |
| Non-GAAP SG&A as % of Revenue | 12.0 | % | Reflects commercial buildout for Journavx and Casgevy. |
| Stock-Based Compensation as % of Revenue | 4.5 | % | Historical average for Vertex. |
| Non-GAAP Effective Tax Rate | 20.0 | % | Management guidance for 2025. |
| Yield on Cash Balances | 4.5 | % | Assumes investment in short-term government securities and money market funds. |
| Diluted Share Count | 258 | Millions | Actual Q4 2024 non-GAAP diluted share count. |
| Annual Share Repurchase Spend | 1,000 | USD Millions | Estimated run-rate to offset SBC dilution. |
| Days Sales Outstanding (DSO) | 50 | Days | Historical average based on specialty pharmacy distribution. |
| Days Inventory Outstanding (DIO) | 165 | Days | Historical average to ensure supply chain security. |
| Capex as % of Revenue | 2.5 | % | Historical average. |
| WACC | 8.0 | % | Standard discount rate for a commercial-stage, cash-rich large-cap biotech. |
| Terminal Growth Rate | 0.0 | % | Conservative assumption due to long-term patent cliffs (Trikafta LOE in late 2030s). |
Data Sources & Benchmarks
- SEC EDGAR: Vertex Pharmaceuticals Form 10-K and 8-K filings.
- Investor Relations: Vertex Q4 2024 Earnings Presentation and Press Release.
- ClinicalTrials.gov: For tracking the progress of povetacicept (Phase 3 IgAN) and VX-880 (Type 1 Diabetes).
- Key peers for benchmarking: Regeneron (REGN), Gilead Sciences (GILD), Biogen (BIIB), and CRISPR Therapeutics (CRSP - partner for Casgevy).
- Industry data sources: Cystic Fibrosis Foundation Patient Registry (crucial for validating total addressable market size).
Sources
- Vertex Pharmaceuticals Q4 and Full Year 2024 Financial Results Press Release (February 10, 2025).
- Vertex Pharmaceuticals 2024 Form 10-K filed with the SEC.
- Vertex Pharmaceuticals Alpine Immune Sciences Acquisition Press Release (April 10, 2024).
- Cystic Fibrosis Foundation (cff.org) for epidemiological data.
Do more with the Vertex Pharmaceuticals model
Frequently asked
What does Vertex Pharmaceuticals do?+
Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and commercializing transformative medicines for people with serious diseases. It established its foundation by treating the underlying cause of cystic fibrosis and is now diversifying into gene therapy, non-opioid pain management, and autoimmune diseases.
What are the primary revenue drivers for Vertex Pharmaceuticals?+
Vertex Pharmaceuticals' revenue is predominantly driven by its Cystic Fibrosis franchise, which accounted for approximately 99% of its 2024 revenue. Future growth is anticipated from new product launches such as the gene therapy Casgevy and the acute pain medication Journavx.
How does the Vertex Pharmaceuticals financial model account for new product launches?+
The Vertex Pharmaceuticals financial model is designed to forecast the cash flow durability of the cystic fibrosis franchise while probability-weighting the commercial ramp of recent and upcoming launches. This includes products like Casgevy, Journavx, and povetacicept, enabling comprehensive equity valuation and pipeline scenario planning.
What is Vertex Pharmaceuticals' capital expenditure strategy?+
Vertex Pharmaceuticals' capital expenditure typically ranges from 2% to 3% of revenue, primarily consisting of growth capex. This investment supports the expansion of R&D laboratory footprints and the buildout of internal cell and genetic therapy manufacturing capabilities in the Boston area.
Can I download an Excel financial model for Vertex Pharmaceuticals?+
Yes, a comprehensive Excel financial model for Vertex Pharmaceuticals is available for download. This general corporate model provides an equity valuation and pipeline scenario planning tool with a forecast horizon from FY2026 to FY2030.
How much does Vertex Pharmaceuticals invest in research and development?+
Vertex Pharmaceuticals operates with an asset-light manufacturing model but makes significant investments in intellectual property and R&D. The financial model assumes R&D expenses at approximately 35% of revenue, reflecting its commitment to discovering and developing new medicines.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Pharmaceuticals Company Financial Models
Browse another company in the same sector.
AbbVie
AbbVie is a global, research-based biopharmaceutical company that discovers and delivers innovative medicines and aesthetic products.
Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on areas of high unmet medical need.
Biogen
Biogen is a global biotechnology company that discovers, develops, and delivers therapies for neurological, immunological, and rare diseases, including multiple sclerosis and Alzheimer's treatments.
Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercialises innovative medicines in areas of unmet medical need.
Incyte
Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of proprietary therapeutics, primarily in haematology, oncology, and inflammation and autoimmunity (IAI).
Johnson & Johnson
Johnson & Johnson is a diversified global healthcare leader engaged in the research, development, manufacture, and sale of pharmaceutical products and medical devices.
Lilly (Eli)
Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and markets human medicines, with a dominant focus on cardiometabolic diseases, oncology, immunology, and neuroscience.
Explore more Healthcare financial model templates.
